

(Print or Type Responses)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL				
OMB Number: 3235-0104				
Estimated average burden				
nours per respons	e 0.5			

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Kolean Chad J	Statemen	t (Month/D			Cellectar Biosciences, Inc. [CLRB]				
(Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE	02/22/2	Issuer (			Reporting Persor all applicable)	Filed(Mon	5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street) FLORHAM, NJ 07932				X_ Officer (give tit	X_ Officer (give title Other (specify		6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person		
(City) (State) (Zip)		Table I - Non-Derivative Securities Beneficially Owned							
1.Title of Security (Instr. 4)		Ве		y Owned		4. Nature of Indire (Instr. 5)	ect Beneficial Ownership		
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.  SEC 1473 (7-02)  Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.									
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title	and Amount of ies Underlying Derivativ	4. Conversion or Exercise For Price of Der	5. Ownership Form of Derivative Security: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
	Date Exercisable	Expiration Date	Title	amount or Number of hares	(I)	(D) or Indirect (I) (Instr. 5)			
Reporting Owners									

	Relationships				
Reporting Owner Name / Address		10% Owner	Officer	Other	
Kolean Chad J C/O CELLECTAR BIOSCIENCES, INC. 100 CAMPUS DRIVE FLORHAM, NJ 07932			Chief Financial Officer		

# **Signatures**

/s/ Asher M. Rubin, Attorney-in-fact for Chad Kolean	02/24/2022	
-*Signature of Reporting Person	Date	

## **Explanation of Responses:**

## No securities are beneficially owned

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

## Remarks:

Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

#### CONFIRMING STATEMENT

This Statement confirms that the undersigned has authorized and designated Asher M. Rubin, Istvan Hajdu, Andrea Reed, and Christina Blakley, each acting singly, to execute and file on the undersigned's behalf all Forms 3, 4, and 5 (including any amendments thereto) that the undersigned may be required to file with the U.S. Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. The authority of Asher M. Rubin, Istvan Hajdu, Andrea Reed, and Christina Blakley under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4, and 5 with regard to the undersigned's ownership of or transactions in securities of Cellectar Biosciences, Inc. unless earlier revoked in writing. The undersigned acknowledges that Asher M. Rubin, Istvan Hajdu, Andrea Reed, and Christina Blakley are not assuming any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Statement revokes the authority of any person named in any prior confirming statement relating to the undersigned's filing obligations with respect to securities of Cellectar Biosciences, Inc. who is not named herein, and this Statement replaces and supersedes any such prior confirming statement.

Dated: February 23, 2022 Signed: /s/ Chad Kolean

Print Name: Chad Kolean